Bonness Enterprises’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.29M | Hold |
36,900
| – | – | 2.99% | 10 |
|
|
2026
Q1 | $8.03M | Hold |
36,900
| – | – | 2.94% | 9 |
|
|
2025
Q4 | $8.43M | Hold |
36,900
| – | – | 2.91% | 6 |
|
|
2025
Q3 | $8.54M | Hold |
36,900
| – | – | 2.8% | 5 |
|
|
2025
Q2 | $6.85M | Hold |
36,900
| – | – | 2.24% | 6 |
|
|
2025
Q1 | $7.73M | Hold |
36,900
| – | – | 2.52% | 5 |
|
|
2024
Q4 | $6.56M | Hold |
36,900
| – | – | 2.3% | 6 |
|
|
2024
Q3 | $7.29M | Hold |
36,900
| – | – | 2.42% | 6 |
|
|
2024
Q2 | $6.33M | Hold |
36,900
| – | – | 2.32% | 7 |
|
|
2024
Q1 | $6.72M | Hold |
36,900
| – | – | 2.42% | 6 |
|
|
2023
Q4 | $5.72M | Hold |
36,900
| – | – | 2.39% | 9 |
|
|
2023
Q3 | $5.5M | Hold |
36,900
| – | – | 2.52% | 8 |
|
|
2023
Q2 | $4.97M | Hold |
36,900
| – | – | 2.24% | 8 |
|
|
2023
Q1 | $5.88M | Hold |
36,900
| – | – | 2.62% | 8 |
|
|
2022
Q4 | $5.96M | Hold |
36,900
| – | – | 2.81% | 8 |
|
|
2022
Q3 | $4.95M | Hold |
36,900
| – | – | 2.63% | 8 |
|
|
2022
Q2 | $5.65M | Hold |
36,900
| – | – | 2.83% | 8 |
|
|
2022
Q1 | $5.98M | Hold |
36,900
| – | – | 2.75% | 7 |
|
|
2021
Q4 | $5M | Buy |
36,900
+300
| +0.8% | +$35.4K | 2.31% | 10 |
|
|
2021
Q3 | $3.95M | Hold |
36,600
| – | – | 2.01% | 15 |
|
|
2021
Q2 | $4.12M | Hold |
36,600
| – | – | 2.08% | 15 |
|
|
2021
Q1 | $3.96M | Hold |
36,600
| – | – | 2.12% | 11 |
|
|
2020
Q4 | $3.92M | Hold |
36,600
| – | – | 2.19% | 9 |
|
|
2020
Q3 | $3.21M | Hold |
36,600
| – | – | 1.88% | 12 |
|
|
2020
Q2 | $3.59M | Hold |
36,600
| – | – | 2.3% | 11 |
|
|
2020
Q1 | $2.79M | Hold |
36,600
| – | – | 2.01% | 13 |
|
|
2019
Q4 | $3.24M | Hold |
36,600
| – | – | 2.04% | 14 |
|
|
2019
Q3 | $2.77M | Hold |
36,600
| – | – | 1.78% | 14 |
|
|
2019
Q2 | $2.66M | Hold |
36,600
| – | – | 1.66% | 15 |
|
|
2019
Q1 | $2.95M | Hold |
36,600
| – | – | 1.92% | 14 |
|
|
2018
Q4 | $3.37M | Hold |
36,600
| – | – | 2.54% | 11 |
|
|
2018
Q3 | $3.46M | Hold |
36,600
| – | – | 2.26% | 11 |
|
|
2018
Q2 | $3.39M | Hold |
36,600
| – | – | 2.4% | 10 |
|
|
2018
Q1 | $3.46M | Sell |
36,600
-1,000
| -3% | -$110K | 2.41% | 9 |
|
|
2017
Q4 | $3.64M | Hold |
37,600
| – | – | 2.47% | 9 |
|
|
2017
Q3 | $3.34M | Hold |
37,600
| – | – | 2.39% | 11 |
|
|
2017
Q2 | $2.73M | Hold |
37,600
| – | – | 2.09% | 12 |
|
|
2017
Q1 | $2.45M | Hold |
37,600
| – | – | 1.96% | 16 |
|
|
2016
Q4 | $2.35M | Sell |
37,600
-2,500
| -6% | -$153K | 2.12% | 16 |
|
|
2016
Q3 | $2.53M | Hold |
40,100
| – | – | 2.1% | 15 |
|
|
2016
Q2 | $2.48M | Hold |
40,100
| – | – | 2.09% | 15 |
|
|
2016
Q1 | $2.29M | Hold |
40,100
| – | – | 1.97% | 17 |
|
|
2015
Q4 | $2.38M | Buy |
40,100
+3,100
| +8% | +$179K | 2.14% | 14 |
|
|
2015
Q3 | $2.01M | Hold |
37,000
| – | – | 1.92% | 16 |
|
|
2015
Q2 | $2.49M | Buy |
37,000
+400
| +1% | +$26.1K | 2.24% | 14 |
|
|
2015
Q1 | $2.14M | Hold |
36,600
| – | – | 1.9% | 17 |
|
|
2014
Q4 | $2.4M | Hold |
36,600
| – | – | 2.07% | 17 |
|
|
2014
Q3 | $2.11M | Hold |
36,600
| – | – | 1.9% | 20 |
|
|
2014
Q2 | $2.06M | Sell |
36,600
-5,000
| -12% | -$262K | 1.87% | 20 |
|
|
2014
Q1 | $2.14M | Hold |
41,600
| – | – | 1.88% | 20 |
|
|
2013
Q4 | $2.2M | Hold |
41,600
| – | – | 1.94% | 18 |
|
|
2013
Q3 | $1.86M | Hold |
41,600
| – | – | 1.79% | 19 |
|
|
2013
Q2 | $1.72M | Buy |
+41,600
| New | +$1.82M | 1.71% | 21 |
|
Other funds holding ABBV
ECSS
Bonness Enterprises's ABBV Position: Q2 2026 in Review
Bonness Enterprises held its AbbVie (ABBV) position steady in Q2 2026 at 36,900 shares worth $9.29M. The position accounts for 2.99% of the portfolio, ranked #10.
Bonness Enterprises first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,153 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Bonness Enterprises held 36,900 shares of AbbVie worth $9.29M as of Q2 2026.
- Bonness Enterprises left its AbbVie share count unchanged in Q2 2026.
- AbbVie made up 2.99% of Bonness Enterprises's portfolio in Q2 2026, its #10 holding.
- Bonness Enterprises first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
- 2,153 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Bonness Enterprises's 13F filing for Q2 2026, filed 9 Jul 2026.